Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer

Abstract Background Adipocyte-derived adiponectin may play a role in the host inflammatory response to cancer. We examined the association of plasma adiponectin with the density of tumor-infiltrating lymphocytes (TILs) in colon cancers and with vitamin D, clinicopathological features, and patient survival. Methods Plasma adiponectin and 25-hydroxyvitamin D [25(OH)D] were analyzed by radioimmunoassay in 600 patients with stage III colon cancer who received FOLFOX-based adjuvant chemotherapy (NCCTG N0147 [Alliance]). TIL densities were determined in histopathological sections. Associations with disease-free survival (DFS), time to recurrence, and overall survival were evaluated by multivariable Cox regression adjusting for potential confounders (ie, body mass index, race, TILs, and N stage). All statistical tests were 2-sided. Results We found a statistically significant reduction in adiponectin, but not 25(OH)D, levels in tumors with high vs low TIL densities (median = 6845 vs 8984 ng/mL; P = .04). A statistically significant reduction in adiponectin was also observed in obese (body mass index >30 kg/m2) vs nonobese patients (median = 6608 vs 12 351 ng/mL; P < .001), in men vs women (median = 8185 vs 11 567 ng/mL; P < .001), in Blacks vs Whites or Asians (median = 6412 vs 8847 vs 7858 ng/mL; P < .03), and in those with fewer lymph node metastases (N1 vs N2: median = 7768 vs 9253 ng/mL; P = .01). Insufficiency of 25(OH)D (<30 ng/mL) was detected in 291 (48.5%) patients. In multivariable analyses, neither adiponectin nor 25(OH)D were associated with a statistically significant difference in DFS, overall survival , or time to recurrence in models adjusted for potential confounders. We found a statistically significant association of TILs with prognosis, yet no such interaction was observed for the association of adiponectin with TILs for DFS. Conclusions Lower circulating adiponectin levels were associated with a statistically significant increase in TIL densities in colon cancers, indicating an enhanced antitumor immune response. In contrast to TILs, neither adiponectin nor 25(OH)D was independently prognostic.

[1]  Jin-Hyeok Hwang,et al.  Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients , 2021, BMC Research Notes.

[2]  Alison R. T. Brenner,et al.  Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored summit. , 2020, CA: a cancer journal for clinicians.

[3]  E. Giovannucci,et al.  Long‐term status of predicted body fat percentage, body mass index and other anthropometric factors with risk of colorectal carcinoma: Two large prospective cohort studies in the US , 2020, International journal of cancer.

[4]  A. Benson,et al.  Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer , 2020, JNCI cancer spectrum.

[5]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  T. Smyrk,et al.  Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. Witkamp,et al.  The association between circulating levels of vitamin D and inflammatory markers in the first 2 years after colorectal cancer diagnosis , 2020, Therapeutic advances in gastroenterology.

[8]  Mingyang Song,et al.  Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. , 2018, European journal of cancer.

[9]  H. Brenner,et al.  Association between Blood 25-Hydroxyvitamin D Levels and Survival in Colorectal Cancer Patients: An Updated Systematic Review and Meta-Analysis , 2018, Nutrients.

[10]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[11]  Haiying Liu,et al.  Low circulating total adiponectin, especially its non-high-molecular weight fraction, represents a promising risk factor for colorectal cancer: a meta-analysis , 2018, OncoTargets and therapy.

[12]  J. Meyerhardt,et al.  Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Stephen B Gruber,et al.  Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer. , 2016, Journal of the National Cancer Institute.

[14]  Meilian Liu,et al.  Adiponectin: a versatile player of innate immunity. , 2016, Journal of molecular cell biology.

[15]  J. Meyerhardt,et al.  Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer , 2015, Cancer Prevention Research.

[16]  H. Suryapranata,et al.  Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[17]  E. Giovannucci,et al.  Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status , 2015, Gut.

[18]  S. Pedersen,et al.  Low Adiponectin Levels and Increased Risk of Type 2 Diabetes in Patients With Myocardial Infarction , 2014, Diabetes Care.

[19]  A. Tenesa,et al.  Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Sargent,et al.  KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance) , 2014, Clinical Cancer Research.

[21]  Kassem M. Makki,et al.  Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines , 2013, ISRN inflammation.

[22]  Ishir Bhan,et al.  Vitamin D-binding protein and vitamin D status of black Americans and white Americans. , 2013, The New England journal of medicine.

[23]  E. Giovannucci,et al.  Plasma Adiponectin and Soluble Leptin Receptor and Risk of Colorectal Cancer: A Prospective Study , 2013, Cancer Prevention Research.

[24]  R. Sacco,et al.  Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study. , 2013, Metabolic syndrome and related disorders.

[25]  B. Schwartz,et al.  Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis , 2012, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[26]  Mary T. Brinkoetter,et al.  Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice , 2012, Gut.

[27]  D. Sargent,et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.

[28]  A. Chumanevich,et al.  Adiponectin deficiency: role in chronic inflammation induced colon cancer. , 2012, Biochimica et biophysica acta.

[29]  Yu Bai,et al.  Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[30]  A. Vaidya,et al.  The Independent Association Between 25‐Hydroxyvitamin D and Adiponectin and Its Relation With BMI in Two Large Cohorts: The NHS and the HPFS , 2012, Obesity.

[31]  W. Willett,et al.  Interactions between Plasma Levels of 25-Hydroxyvitamin D, Insulin-Like Growth Factor (IGF)-1 and C-Peptide with Risk of Colorectal Cancer , 2011, PloS one.

[32]  J. Meyerhardt,et al.  Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Matthews,et al.  Serum adiponectin in relation to body mass index and other correlates in black and white women. , 2011, Annals of epidemiology.

[34]  M. Currie,et al.  Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer , 2010, British Journal of Cancer.

[35]  J. Fenton,et al.  Adipokine regulation of colon cancer: Adiponectin attenuates interleukin‐6‐induced colon carcinoma cell proliferation via STAT‐3 , 2010, Molecular carcinogenesis.

[36]  A. Hildesheim,et al.  Establishment and Operation of a Biorepository for Molecular Epidemiologic Studies in Costa Rica , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[37]  D. Dumitrascu,et al.  Metabolic syndrome and risk of subsequent colorectal cancer. , 2009, World journal of gastroenterology.

[38]  W. Willett,et al.  Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer , 2009, British Journal of Cancer.

[39]  P. Libby,et al.  Adiponectin Inhibits Pro-inflammatory Signaling in Human Macrophages Independent of Interleukin-10* , 2009, The Journal of Biological Chemistry.

[40]  C. Fox,et al.  Common Variants in the Adiponectin Gene (ADIPOQ) Associated With Plasma Adiponectin Levels, Type 2 Diabetes, and Diabetes-Related Quantitative Traits , 2008, Diabetes.

[41]  C. Ulrich,et al.  Shedding light on colorectal cancer prognosis: vitamin d and beyond. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Holick.  Vitamin D deficiency. , 2007, The New England journal of medicine.

[43]  J. Jürimäe,et al.  Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. , 2007, American journal of physiology. Endocrinology and metabolism.

[44]  E. Giovannucci,et al.  Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. , 2007, American journal of preventive medicine.

[45]  J. K. Kim,et al.  Adiponectin Is a Negative Regulator of NK Cell Cytotoxicity1 , 2006, The Journal of Immunology.

[46]  Matthias Blüher,et al.  Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. , 2004, The Journal of clinical endocrinology and metabolism.

[47]  E. Nieschlag,et al.  Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy , 2004, Clinical endocrinology.

[48]  M. Cogswell,et al.  Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. , 2002, The American journal of clinical nutrition.

[49]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[50]  B. Hollis,et al.  Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. , 1997, Methods in enzymology.